As such, the indirect disruption of TBX2 function via targeting specific epigenetic modifiers presents an attractive therapeutic opportunity for the treatment of poor outcome, TBX2-overexpressing breast cancers and other tumour types with TBX2 dependency. The gene discussed is TBX2; the disease is breast carcinoma.